QUARTERLY PORTFOLIO UPDATE

Portfolio Company: Gamma Healthcare Services
Fund: HealthVest Partners II
Quarter: Q3 2025
Investment Date: March 2023
Current Hold Period: 2.5 years

PERFORMANCE SUMMARY

Financial Performance:
- Q3 2025 Revenue: $42M (vs $38M budget, +10.5% beat)
- Q3 2025 EBITDA: $11.2M (26.7% margin vs 25% target)
- YTD Revenue: $118M (+18% YoY)
- YTD EBITDA: $31M (+22% YoY)
- LTM Revenue: $156M
- LTM EBITDA: $41M

Organic Growth: +12%
Acquisition Growth: +6%
Total Growth: +18% YoY

Key Performance Indicators:
- Patient visits: 128,000 (Q3)
- Locations: 47 clinics (added 5 in Q3)
- Same-clinic growth: +8%
- Staff retention: 87%
- Net Promoter Score: 76

OPERATIONAL HIGHLIGHTS

Value Creation Initiatives:
✓ Completed EHR system migration (Epic implementation)
✓ Launched telehealth platform (12% of visits now virtual)
✓ Opened 3 de novo clinics, acquired 2 practices
✓ Recruited Chief Medical Officer from Mayo Clinic
✓ Negotiated improved payer contracts (+3% reimbursement rates)

Digital Transformation:
- Patient portal adoption: 68% (up from 42%)
- Online appointment booking: 54% of new patients
- AI-powered triage system: reduced wait times by 23%

Geographic Expansion:
- Entered 2 new states (Texas, Arizona)
- Pipeline: 8 additional acquisition targets identified
- Market density strategy: 3+ clinics per metro area

INVESTMENT METRICS

Current Valuation:
- Entry valuation: $180M (7.5x EBITDA)
- Current valuation: $369M (9.0x LTM EBITDA)
- Unrealized gain: $189M
- MOIC (unrealized): 2.05x
- IRR (unrealized): 35%

Capital Structure:
- Equity: $90M
- Senior debt: $70M (4.8x leverage at entry, now 3.2x)
- Debt service coverage ratio: 2.8x
- Cash balance: $12M

STRATEGIC OUTLOOK

Near-term priorities (6-12 months):
1. Complete integration of Q3 acquisitions
2. Launch chronic care management program
3. Expand to 55 total locations
4. Implement revenue cycle optimization
5. Build out data analytics capabilities

Exit Planning:
- Target exit timing: Q2-Q3 2026 (3-3.5 year hold)
- Exit multiple target: 10-11x EBITDA
- Preferred exit route: Strategic sale to large healthcare system
- Alternative: Secondary buyout to larger PE fund
- Backup: IPO (requires $500M+ valuation)

Potential Buyers Identified:
- UnitedHealth Group (Optum division)
- CVS Health (HealthHUB strategy)
- Humana (CenterWell acquisition strategy)
- Large regional health systems (5 identified)

RISKS & MITIGATION

Key Risks:
1. Regulatory: CMS reimbursement cuts (10% probability)
   Mitigation: Diversify payer mix, increase commercial insurance

2. Competition: New clinic openings by competitors in core markets
   Mitigation: First-mover advantage, superior patient experience

3. Labor: Healthcare worker shortage driving wage inflation
   Mitigation: Retention programs, technology to improve productivity

4. Integration: Cultural challenges with acquired practices
   Mitigation: Robust integration playbook, local autonomy model

BOARD RECOMMENDATIONS

1. APPROVED: $8M growth capex for 5 new clinics in 2026
2. APPROVED: $3M investment in AI diagnostic tools
3. UNDER REVIEW: Add-on acquisition of 6-clinic group ($22M)
4. DEFERRED: International expansion (revisit in 2026)

Next Board Meeting: January 15, 2026
